Response to Pembrolizumab in Advanced Anal Squamous Cell Carcinoma With High TMB and PD-L1 and PD-L2 Amplification

Nelson, 2017, Epidemiology of anal canal cancer, Surg Oncol Clin N Am, 26, 9, 10.1016/j.soc.2016.07.001

Eng, 2006, Anal cancer: current and future methodology, Cancer Invest, 24, 535, 10.1080/07357900600815208

Rao, 2020, International Rare Cancers Initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct, J Clin Oncol, 38, 2510, 10.1200/JCO.19.03266

Marabelle, 2020, Pembrolizumab for previously treated advanced anal squamous cell carcinoma: pooled results from the KEYNOTE-028 and KEYNOTE-158 studies, J Clin Oncol, 38, 4020, 10.1200/JCO.2020.38.15_suppl.4020

Cummings, 2005, Anal carcinoma, 83

Ott, 2017, Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal, Ann Oncol Off J Eur Soc Med Oncol, 28, 1036, 10.1093/annonc/mdx029

Goodman, 2018, Prevalence of PDL1 amplification and preliminary response to immune checkpoint blockade in solid tumors, JAMA Oncol, 4, 1237, 10.1001/jamaoncol.2018.1701

Weinberg, 2017, Molecular characterization of squamous cell carcinoma of the anal canal (SCCA), J Clin Oncol, 35, 538, 10.1200/JCO.2017.35.4_suppl.538

Haanen, 2020, Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy, Ann Oncol, 31, 724, 10.1016/j.annonc.2020.03.285